Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
about
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune diseaseRituximab: A Magic Bullet for PemphigusRobust memory responses against influenza vaccination in pemphigus patients previously treated with rituximabPersistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years.Management of pemphigusClinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisitaRituximab therapy in pemphigus and other autoantibody-mediated diseases.Setting the target for pemphigus vulgaris therapy.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris.An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab.The dual nature of interleukin-10 in pemphigus vulgaris.Immune cellular regulation on autoantibody production in pemphigus.The emerging role of rituximab in autoimmune blistering diseases.A clinical audit of high-cost and off-label drug use in dermatology.Immune response in pemphigus and beyond: progresses and emerging concepts.Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.Targeting B cells in treatment of autoimmunity.The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.Human regulatory B cells in health and disease: therapeutic potential.Rituximab, a new treatment for difficult-to-treat chronic erythema multiforme major? Five cases.Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.Successful treatment of severe anti-p200 pemphigoid in a heart transplant recipient with a single cycle of rituximab.Development of bullous pemphigoid during nivolumab therapy.Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients.Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up.Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.Detailed profiling of anti-desmoglein autoantibodies identifies anti-Dsg1 reactivity as a key driver of disease activity and clinical expression in pemphigus vulgaris.Rituximab in pemphigus.Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris.Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up.Sarcoidosis following successful treatment of pemphigus vulgaris with rituximab: a rituximab-induced reaction further supporting B-cell contribution to sarcoidosis pathogenesis?Long-term results of rituximab-intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy.B Cell Modulation Strategies in Autoimmune Diseases: New Concepts.Targeting B Cells and Plasma Cells in Autoimmune Diseases.Autoimmune Diseases and Their Manifestations on Oral Cavity: Diagnosis and Clinical Management.Emerging treatment options for the management of pemphigus vulgaris.PemphigusAutoreactive IgG and IgA B Cells Evolve through Distinct Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris
P2860
Q28276800-3414967C-74E7-46A4-A576-58CF5A01BE93Q33741941-AA646274-ACAD-4211-9626-7DE0E1A212B3Q33798060-BFD5A0DF-0054-498D-A814-16FA123021C5Q34964558-F1A49EA9-B4BE-40D3-9C14-344BE55DDC58Q35173849-41DB4535-357F-44D1-82BF-DD29F1B9E994Q37055162-7BBD4B67-710C-439F-B1A4-AEEA948355E4Q37620483-5721FC3D-B331-4747-934F-F7C45254930FQ37677416-5A18A017-ECE7-4356-98AA-4F6D4BDFA1C6Q38154934-DFEB850B-A1B9-4439-AC50-A5D4FA01727FQ38179053-8A099099-B8B0-4805-A61D-92B9777676B0Q38245848-36FC205F-409B-4ABC-8B7A-BFFFFD5F76C6Q38281273-604C6AF8-2AE4-49D5-85BA-F35AEA53DBF3Q38307341-F9DA2C88-61AF-4B74-AEFB-A0A9805BDBDCQ38384497-DEDF239D-7714-4BED-B130-379095369F78Q38582166-ABE3CC34-7417-45E4-A966-5344289D0C72Q38644346-95693826-5A4B-4E0E-88A4-E0DC6C80E1D4Q38747187-E9DF69E1-E637-440D-A4DD-A430CA20C384Q38975656-1C752A5A-C991-4FFE-8B90-C693ED2BDDC5Q39096598-B3D11BBF-A88B-444B-BC50-AE97BCD88C19Q39156034-E77C3847-D75A-4F45-8261-96A021A730A4Q41001080-E6EC9DA2-B943-4B13-868A-E280DFEFB89CQ41846224-B8D08149-14DE-4A46-A05B-7534898FBB68Q42291227-19EE6937-10DE-4758-95B6-E8674B1AF51CQ42356323-54411E52-0EB0-4A82-9703-0D0C9E89009DQ42667029-EA6EA006-9492-4831-AA0D-F048FF490822Q47219879-E0AF3F5B-8F55-4217-98E9-1C03B6171374Q47977153-A2AE4207-AEB2-4B0B-8844-D48BBC1ED7A2Q48142572-347B0AD5-77A9-4C6A-8065-CAB851E55670Q48698328-E6CE647B-3E8B-4FB8-AE0D-84D6A729D6D2Q50075561-02B4D74D-2BD2-4893-8ABE-67689B527767Q50786186-C8FAE9EC-383F-499A-9447-476F108B3158Q53126755-A1882870-3F13-431A-8A23-C754971E481AQ53199038-C4289C01-7A98-4643-8C3C-449681ED3CDBQ53786801-C8FAFE37-54F5-43A6-A6B9-CEA0E9177DD8Q54980047-0E8D6BB5-022D-4A27-8221-8DF0A43B5660Q55234556-DC65EB0B-4769-44F3-908E-C0A46C65B759Q55413268-E5A6C796-D309-4DEF-A455-23D96BE2827BQ55433740-D1384B12-79F8-4470-B19F-B20F6B8A2FFEQ56603745-0BD8F01E-22EC-4860-9F1A-0CD521311CD1Q58697437-BB884332-410C-4928-A940-1655EE0EDA0D
P2860
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Long-term remissions of severe ...... of desmoglein B cell response.
@en
Long-term remissions of severe ...... of desmoglein B cell response.
@nl
type
label
Long-term remissions of severe ...... of desmoglein B cell response.
@en
Long-term remissions of severe ...... of desmoglein B cell response.
@nl
prefLabel
Long-term remissions of severe ...... of desmoglein B cell response.
@en
Long-term remissions of severe ...... of desmoglein B cell response.
@nl
P2093
P2860
P1476
Long-term remissions of severe ...... of desmoglein B cell response
@en
P2093
Annick Lim
Brigitte Dreno
Brigitte Le Mauff
Brigitte Lemercier
Catherine Picard
Catherine Prost
Christine Pauwels
Christophe Bedane
Damien Picard
Emmanuel Delaporte
P2860
P304
P356
10.1126/SCITRANSLMED.3005166
P407
P577
2013-03-01T00:00:00Z